Adrian Esterman receives funding from the NHMRC, MRFF and ARC. COVID rarely rates a mention in the news these days, yet it hasn’t gone away. SARS-CoV-2, the virus that causes COVID, is still with us.

A person was killed in a multi-vehicle wreck on the 15 Freeway at the Cajon Pass on Tuesday afternoon, officials said. The crash was reported about 2:30 p.m. Dec. 9 on the northbound side of the ...

Despite some public backlash and a lawsuit from the state Attorney General, El Cajon City Council members have no plans to stop sharing license plate surveillance data with out-of-state police ...

EL CAJON, Calif. — Tenants at an El Cajon apartment complex are reporting a severe cockroach infestation, with one unit described as "severely infested." Residents of the Artesia apartments on ...

SAN BERNARDINO — The San Jacinto Tigers controlled the clock and collected back-to-back nonleague September victories over the Cajon Cowboys with their 23-13 win on Friday. Despite allowing a safety ...

Mariene Branham knocks on a lot of doors. As an immigrant advocate in El Cajon, part of her job is to check in on people and see how they’re holding up amid President Donald Trump’s mass deportation ...

Please provide your email address to receive an email when new articles are posted on . Investigational therapies to lower Lp(a) include antisense oligonucleotide therapies and small interfering RNA ...

“Sustainability is a core part of how we operate at LP,” said LP Chair and CEO Brad Southern. “It informs our decision-making, strengthens our performance, and reflects our long-standing commitment to ...

Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy ...

Federal law enforcement descended in unincorporated El Cajon on Thursday to execute a search warrant at a business suspected of knowingly employing undocumented immigrants, according to the U.S.

An ribonucleic acid (RNA) inhibitor, olpasiran (Amgen), which has shown it can lower lipoprotein(a) [Lp(a)] levels in patients with cardiovascular disease (CVD), has demonstrated in a phase 2 trial ...

Muvalaplin, an oral drug, significantly reduces Lp(a) levels by disrupting apo(a) and apoB bonding, achieving up to 85.5% reduction in a phase 2 study. Lp(a) is a genetically driven cardiovascular ...